Janney Capital upgraded BioDelivery Sciences International (NASDAQ:BDSI) from Neutral to Buy in a statement released earlier today.
- Updated: September 23, 2016
Having a price of $2.65, BioDelivery Sciences International (NASDAQ:BDSI) traded 6.89% higher on the day. With the last close down -3.18% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. BioDelivery Sciences International has recorded a 50-day average of $2.55 and a two hundred day average of $2.71. Volume of trade was up over the average, with 1,206,545 shares of BDSI changing hands over the typical 774,850
Janney Capital has upgraded BioDelivery Sciences International (NASDAQ:BDSI) from Neutral to Buy in a statement released on 09/23/2016.
On Thursday May 12, 2016, Piper Jaffray released a statement on BioDelivery Sciences International (NASDAQ:BDSI) dropped the target price from $6.00 to $4.00 that suggested an upside of 0.92%.
With a total market value of $0, BioDelivery Sciences International has with a one year low of $1.86 and a one year high of $7.04 .
A total of 8 brokerages have issued a ratings update on BioDelivery Sciences International. Three brokerages rating the company a strong buy, four brokerages rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $9.25.
General Company Details For BioDelivery Sciences International (NASDAQ:BDSI)
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.